Fly News Breaks for November 11, 2019
Nov 11, 2019 | 06:44 EDT
Mizuho analyst Difei Yang raised her price target for FibroGen to $72 from $65 after the company reported MACE data from the global Phase 3 clinical trials of roxadustat. The data were positive with non-inferiority to placebo in the non dialysis-dependent setting and non-inferiority versus standard of care erythropoiesis stimulating agents in the dialysis-dependent setting, Yang tells investors in a research note. She believes the "path to approval is clear" and reiterates a Buy rating on FibroGen.
News For FGEN From the Last 2 Days
There are no results for your query FGEN